Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19

BACKGROUND: CoronaVac, an inactivated whole-virion vaccine against COVID-19, has been shown to be safe with acceptable antibody responses by various clinical trials. AIMS: The objective was to investigate the post-vaccination antibody levels of both symptomatic and asymptomatic healthcare workers wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozturk, Derya, Gareayaghi, Nesrin, Tahtasakal, Ceren Atasoy, Calik, Mustafa, Altinbilek, Ertugrul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743087/
https://www.ncbi.nlm.nih.gov/pubmed/35001336
http://dx.doi.org/10.1007/s11845-021-02883-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743087/
https://www.ncbi.nlm.nih.gov/pubmed/35001336
http://dx.doi.org/10.1007/s11845-021-02883-x

Ejemplares similares